Clinical Trial · NCT04239742

F18-PSMA-1007 PET for Early Biochemical Recurrence of Prostate Cancer

Overview

18F-PSMA-1007 is a new radiopharmaceutical for the detection of prostate cancer with potential benefits over the registered 18F-Fluciclovine (Axumin). The main potential benefit is the higher detection rate of PSMA compared to Fluciclovin in the low PSA range. It may therefore be more sensitive in detecting local disease in case of biochemical recurrens. The investigators aim to compare the detection efficacy of 18F-PSMA-1007 to 18F-Fluciclovin in prostate cancer patients with biochemical recurrence (PSA levels 0.2-5 ng/ml).

Sponsor

Radboud University Medical Center

Phase

N/A

Contacts

James Nagarajah, MD, PhD (CONTACT)

james.nagarajah@radboudumc.nl

0031243614510

Willemijn van Gemert, MD, PhD (CONTACT)

willemijn.vangemert@radboudumc.nl

0031243614510

James Nagarajah, MD, PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04239742

Drug / Compound

PSMA-1007

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Fluciclovine

Isotope(s):

Target(s):

Amino Acid Transport

Ligand Class: Small Molecules

Eligibility

Inclusion

Biochemical recurrence with (rising) PSA-levels of 0.2-5.0 ug/L
PSA level determined \<8 weeks before study participation
Prior local treatment with curative intent
Referred by urologist for PET/CT for localization of the recurrence
Histologically proven adenocarcinoma of the prostate
Males ≥ 18 years

Exclusion

Other cancer \<2 years prior to biochemical recurrence of prostate cancer
Contra-indications for PET-CT: claustrophobia or inability to lay still for the duration of the exam.